Clinical Testing
VIRGINIA TECH
MOLECULAR DIAGNOSTICS LAB
Clinical Testing
The laboratory offers analytically validated, clinically reportable molecular diagnostic testing under CLIA and CAP oversight. Ordering pathways, specimen requirements, and turnaround expectations are stated explicitly. The current clinically reportable menu is the Oncomine Myeloid Assay. The Oncomine Comprehensive Assay Plus is under analytical validation and is not currently available for clinical ordering.
Research use capabilities
Long-read sequencing on the Oxford Nanopore GridION is available for research-use structural-variant and rearrangement analysis.
The Ion Torrent Genexus in research-use mode offers sample-to-report short-read sequencing for research applications distinct from the clinical menu.
Biomolecular interaction analysis on the Biacore 3000 is available for research-use translational biomarker studies.
Digital PCR on the Bio-Rad QX ONE is available for research-use quantification and rare-variant detection outside validated clinical use.
Ordering procedures
1
Contact Clinical Testing intake to establish a laboratory account.
2
Obtain the requisition form and unique-identifier documentation.
3
Collect and label the specimen according to the Specimen Submission Guide.
4
Ship or courier the specimen within the stability window.
5
Receive the report through the agreed reporting channel.
Turnaround time
Turnaround time is reported per assay from a defined starting endpoint to report sign-out. Specific values are drawn from validated performance data.
Report structure
Clinical reports separate the analytical result, molecular interpretation, and framework for potential clinical relevance, in a form aligned with professional oncology variant-interpretation guidelines. Reports are reviewed and signed out by the Medical Director. A redacted example report may be requested through Clinical Testing intake.
Billing and coverage
Billing arrangements and payer contracting information are provided on request through laboratory administration. Coverage of a specific assay for a specific indication is determined by the patient's payer.
Pathology review
The Medical Director, Douglas Grider, M.D., holds clinical responsibility for reporting and interpretation. Ordering pathologists at referring institutions may request coordination directly through Clinical Testing intake.
Technical support
Directed technical questions regarding specimen handling, requisition, or transport to the General Supervisor, Sarah Stern, through Clinical Testing intake.
Contact Us
Sarah Stern
General Supervisor
Virginia Tech Molecular Diagnostic Lab
sterns@vt.edu
540-526-2630